Rhumbline Advisers Boosts Stake in Geron Co. (NASDAQ:GERN)

Rhumbline Advisers raised its position in shares of Geron Co. (NASDAQ:GERN) by 1.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 834,844 shares of the biopharmaceutical company’s stock after buying an additional 12,070 shares during the quarter. Rhumbline Advisers owned about 0.14% of Geron worth $2,955,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Readystate Asset Management LP bought a new stake in Geron in the third quarter worth $58,000. Rovin Capital UT ADV grew its stake in shares of Geron by 26.9% in the 4th quarter. Rovin Capital UT ADV now owns 17,270 shares of the biopharmaceutical company’s stock worth $61,000 after buying an additional 3,660 shares in the last quarter. Monterey Private Wealth Inc. purchased a new position in shares of Geron in the 4th quarter worth $63,000. Empowered Funds LLC bought a new stake in shares of Geron in the 3rd quarter worth about $67,000. Finally, US Bancorp DE raised its position in shares of Geron by 68.4% during the 3rd quarter. US Bancorp DE now owns 18,296 shares of the biopharmaceutical company’s stock valued at $83,000 after buying an additional 7,429 shares in the last quarter. Institutional investors own 73.71% of the company’s stock.

Geron Stock Up 1.1 %

NASDAQ:GERN opened at $1.76 on Friday. The stock has a fifty day simple moving average of $2.93 and a 200-day simple moving average of $3.77. The company has a current ratio of 2.89, a quick ratio of 2.74 and a debt-to-equity ratio of 0.04. The company has a market cap of $1.06 billion, a price-to-earnings ratio of -5.50 and a beta of 0.53. Geron Co. has a twelve month low of $1.46 and a twelve month high of $5.34.

Geron (NASDAQ:GERN) last announced its quarterly earnings data on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.04). The company had revenue of $47.54 million during the quarter, compared to analyst estimates of $45.29 million. Geron had a negative net margin of 682.48% and a negative return on equity of 67.53%. Analysts anticipate that Geron Co. will post -0.25 EPS for the current year.

Analysts Set New Price Targets

GERN has been the subject of several recent research reports. B. Riley lowered Geron from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $3.50 to $2.00 in a research report on Thursday. HC Wainwright cut Geron from a “buy” rating to a “neutral” rating in a report on Wednesday. Barclays restated an “overweight” rating and set a $4.00 price target (down previously from $9.00) on shares of Geron in a report on Thursday. Needham & Company LLC lowered their price target on Geron from $7.00 to $5.00 and set a “buy” rating for the company in a research report on Thursday. Finally, Stifel Nicolaus cut their price objective on shares of Geron from $8.00 to $4.00 and set a “buy” rating on the stock in a research report on Thursday. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $5.68.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.